Qiagen has announced new artificial intelligence (AI) capabilities to help researchers analyse complex biological and genomic data faster while keeping the scientific evidence behind the results visible.
The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows.
The new offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights (QDI), whose bioinformatics solutions are used by around 150,000 users. The global market for AI in bioinformatics is projected to more than double from about $12 billion in 2026 to more than $25 billion by 2031, according to Mordor Intelligence.
As researchers increasingly use AI to analyse growing volumes of biological and genomic data, speed alone is not enough. QIAGEN combines AI with expert-reviewed biological, genomic and clinical information so scientists can examine the evidence behind the results.
The launches are part of a broader rollout of AI across QIAGEN Digital Insights, including AI-powered translation in QIAGEN Clinical Insight (QCI) Interpret and machine learning combined with expert-reviewed information in Franklin by QIAGEN.
